2016 Fiscal Year Final Research Report
Activation of insulin-like growth factor as a biomarker for cancer development and growth
| Project/Area Number |
26460968
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
SETOYAMA TAKESHI 京都大学, 医学部附属病院がんセンター, 医員 (80760595)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | インスリン様増殖因子 / バイオマーカー / 分子標的治療 / 非膵島細胞腫瘍性低血糖 |
|---|
| Outline of Final Research Achievements |
We have been reported the usefulness of insulin-like growth factor (IGF) as a therapeutic target using IGF neutralizing antibody. This antibody can neutralize only bioactive IGF activated in the tumor microenvironment and does not affect the physiological molecular form, IGF-IGF binding protein complex. This characteristics of antibody can lead to not only reduction of the systemic adverse effect but also tumor-specific drug delivery. It is essential for the accurate dosage adjustment and prediction of therapeutic and adverse effect to measure the level of bioactive IGF. We successfully develop the novel assay for the detection of bioactive IGF in the blood. Furthermore, we clarified that bioactive IGF-2 was elevated in a case of tumor-associated hypoglycemia except insulin-producing tumor using this assay.
|
| Free Research Field |
消化器内科
|
